GLY 103
Alternative Names: GLY-103Latest Information Update: 13 Jul 2023
Price :
$50 *
At a glance
- Originator Glycan Therapeutics
- Developer Glycan Therapeutics; Unknown
- Class Anticoagulants; Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Deep vein thrombosis
Most Recent Events
- 07 Jul 2023 Preclinical trials in Deep vein thrombosis (Prevention) in China (unspecified route), prior to July 2023 (Glycan Therapeutics pipeline, July 2023)
- 07 Jul 2023 Glycan Therapeutics plans a phase I trial for Deep vein thrombosis (Prevention) (Glycan Therapeutics pipeline, July 2023)